(Q30444698)

21 June 2017

1 reference

title

Cancer-associated bone disease (English)

1 reference

21 June 2017

1 reference

2

Theresa A Guise

1 reference

21 June 2017

Sue A Brown

1

1 reference

21 June 2017

publication date

1 September 2007

1 reference

Current osteoporosis reports

21 June 2017

published in

1 reference

21 June 2017

volume

5

1 reference

21 June 2017

issue

3

1 reference

21 June 2017

page(s)

120-127

1 reference

https://scigraph.springernature.com/pub.10.1007/s11914-007-0027-8

21 June 2017

exact match

0 references

cites work

Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force

1 reference

https://api.crossref.org/works/10.1007%2FS11914-007-0027-8

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-007-0027-8

Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-007-0027-8

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11914-007-0027-8

Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane

21 January 2018

1 reference

12 December 2020

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.

1 reference

12 December 2020

The components of excess mortality after hip fracture

1 reference

12 December 2020

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

1 reference

12 December 2020

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

1 reference

12 December 2020

Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer

1 reference

12 December 2020

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

1 reference

12 December 2020

Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma

1 reference

12 December 2020

Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

1 reference

12 December 2020

Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years.

1 reference

12 December 2020

Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma

1 reference

12 December 2020

NCCN Task Force Report: Bone Health and Cancer Care

1 reference

12 December 2020

Therapy Insight: osteoporosis during hormone therapy for prostate cancer

1 reference

12 December 2020

Mechanisms of bone metastasis

1 reference

12 December 2020

Osteoporosis due to cancer treatment: pathogenesis and management

1 reference

12 December 2020

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer

1 reference

12 December 2020

Basic mechanisms responsible for osteolytic and osteoblastic bone metastases

1 reference

12 December 2020

Serial Markers of Bone Turnover in Men with Metastatic Prostate Cancer Treated with Zoledronic Acid for Detection of Bone Metastases Progression

1 reference

12 December 2020

Fracture risk among breast cancer survivors: results from the Women's Health Initiative Observational Study.

1 reference

12 December 2020

Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)

1 reference

12 December 2020

Osteonecrosis of the jaw: more research needed

1 reference

12 December 2020

Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation

1 reference

12 December 2020

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

1 reference

12 December 2020

A high incidence of vertebral fracture in women with breast cancer

1 reference

12 December 2020

Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer

1 reference

12 December 2020

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

1 reference

12 December 2020

Fracture risk with multiple myeloma: a population-based study

1 reference

12 December 2020

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

1 reference

12 December 2020

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

12 December 2020

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

1 reference

12 December 2020

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

1 reference

12 December 2020

Skeletal complications of breast cancer therapies

1 reference

12 December 2020

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

1 reference

12 December 2020

Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy

1 reference

12 December 2020

Skeletal fractures negatively correlate with overall survival in men with prostate cancer

1 reference

12 December 2020

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

12 December 2020

Risk of fracture after androgen deprivation for prostate cancer

1 reference

12 December 2020

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

1 reference

12 December 2020

Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial

1 reference

12 December 2020

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

1 reference

12 December 2020

Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

1 reference

12 December 2020

The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study

1 reference

12 December 2020

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

1 reference

12 December 2020

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

12 December 2020

Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results

1 reference

12 December 2020

Low bone mineral density in hormone-naïve men with prostate carcinoma

1 reference

12 December 2020

Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17

1 reference

12 December 2020

Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial

1 reference

12 December 2020

10.1007/S11914-007-0027-8

Identifiers

DOI

1 reference

Dimensions Publication ID

21 June 2017

1039982217

0 references

1 reference